Schedule 13G ownership disclosure
Cullinan Therapeutics Inc
Common Stock, par value $0.0001 per share (the "Shares") · CUSIP: 230031106
Event date: 2025-07-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Citadel Advisors LLC
Shares: 2,511,191.00 · Class: 4.3%
- Citadel Advisors Holdings LP
Shares: 2,511,191.00 · Class: 4.3%
- Citadel GP LLC
Shares: 2,511,191.00 · Class: 4.3%
- Citadel Securities LLC
Shares: 497,935.00 · Class: 0.8%
- Citadel Securities Group LP
Shares: 497,935.00 · Class: 0.8%
- Citadel Securities GP LLC
Shares: 497,935.00 · Class: 0.8%
- Kenneth Griffin
Shares: 3,009,126.00 · Class: 5.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-074813
- Form type
- SCHEDULE 13G
- Filer
- CITADEL ADVISORS LLC
- CIK
- CIK 1423053
- Filed
- Aug 06, 2025
- Reporting period
- Jul 30, 2025
- Description
- Schedule 13G beneficial ownership